209 related articles for article (PubMed ID: 31207358)
1. Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort.
Dressel A; Schmidt B; Schmidt N; Laufs U; Fath F; Chapman MJ; Grammer TB; März W
Vascul Pharmacol; 2019 Sep; 120():106566. PubMed ID: 31207358
[TBL] [Abstract][Full Text] [Related]
2. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
Arrieta A; Hong JC; Khera R; Virani SS; Krumholz HM; Nasir K
JAMA Cardiol; 2017 Dec; 2(12):1369-1374. PubMed ID: 29049467
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults.
Davis LE; Pogge EK
High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):331-338. PubMed ID: 32651891
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective.
Kumar R; Tonkin A; Liew D; Zomer E
Int J Cardiol; 2018 Sep; 267():183-187. PubMed ID: 29731350
[TBL] [Abstract][Full Text] [Related]
5. Application of PCSK9 Inhibitors in Practice.
Kaufman TM; Warden BA; Minnier J; Miles JR; Duell PB; Purnell JQ; Wojcik C; Fazio S; Shapiro MD
Circ Res; 2019 Jan; 124(1):32-37. PubMed ID: 30605414
[TBL] [Abstract][Full Text] [Related]
6. Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial.
Virani SS; Akeroyd JM; Nambi V; Michos ED; Morris PB; Nasir K; Smith SC; Stone NJ; Petersen LA; Ballantyne CM
Circulation; 2019 Jan; 139(3):410-412. PubMed ID: 30586689
[No Abstract] [Full Text] [Related]
7. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand.
Kongpakwattana K; Ademi Z; Chaiyasothi T; Nathisuwan S; Zomer E; Liew D; Chaiyakunapruk N
Pharmacoeconomics; 2019 Oct; 37(10):1277-1286. PubMed ID: 31243736
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease.
Nastasi DR; Moxon JV; Norman R; Trollope AF; Rowbotham S; Quigley F; Jenkins J; Golledge J
J Vasc Surg; 2021 Apr; 73(4):1396-1403.e3. PubMed ID: 32891803
[TBL] [Abstract][Full Text] [Related]
9. Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic.
Zafrir B; Jubran A
Cardiovasc Ther; 2018 Oct; 36(5):e12439. PubMed ID: 29863817
[TBL] [Abstract][Full Text] [Related]
10. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
Sabatine MS; De Ferrari GM; Giugliano RP; Huber K; Lewis BS; Ferreira J; Kuder JF; Murphy SA; Wiviott SD; Kurtz CE; Honarpour N; Keech AC; Sever PS; Pedersen TR
Circulation; 2018 Aug; 138(8):756-766. PubMed ID: 29626068
[TBL] [Abstract][Full Text] [Related]
11. Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease.
Mallya UG; Boklage SH; Koren A; Delea TE; Mullins CD
Pharmacoeconomics; 2018 Jan; 36(1):115-126. PubMed ID: 29181773
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
13. PCSK9 inhibitor valuation: A science-based review of the two recent models.
Baum SJ; Cannon CP
Clin Cardiol; 2018 Apr; 41(4):544-550. PubMed ID: 29512936
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan.
Kodera S; Morita H; Kiyosue A; Ando J; Takura T; Komuro I
Circ J; 2018 Sep; 82(10):2602-2608. PubMed ID: 30033948
[TBL] [Abstract][Full Text] [Related]
15. Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions.
Doshi JA; Li P; Puckett JT; Pettit AR; Raman S; Parmacek MS; Rader DJ
Value Health; 2020 Feb; 23(2):209-216. PubMed ID: 32113626
[TBL] [Abstract][Full Text] [Related]
16. PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
Chamberlain AM; Gong Y; Shaw KM; Bian J; Song WL; Linton MF; Fonseca V; Price-Haywood E; Guhl E; King JB; Shah RU; Puro J; Shenkman E; Pawloski PA; Margolis KL; Hernandez AF; Cooper-DeHoff RM
J Am Heart Assoc; 2019 May; 8(9):e011246. PubMed ID: 31020929
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease.
Stam-Slob MC; van der Graaf Y; de Boer A; Greving JP; Visseren FLJ
Int J Cardiol; 2018 Feb; 253():148-154. PubMed ID: 29306457
[TBL] [Abstract][Full Text] [Related]
18. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
[TBL] [Abstract][Full Text] [Related]
19. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors.
Hines DM; Rane P; Patel J; Harrison DJ; Wade RL
Vasc Health Risk Manag; 2018; 14():409-418. PubMed ID: 30573963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
